Neoleukin Therapeutics Inc

Research Neoleukin Therapeutics Inc (NGNE) on Bullrun: market cap USD 510.09M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNGNE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 510.09M
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-USD 90.35M
• Free cash flow-USD 78.36M

Valuation Snapshot

latest market cap is USD 510.09M.

About Neoleukin Therapeutics Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.

Frequently asked questions

What is Neoleukin Therapeutics Inc's market cap?

Neoleukin Therapeutics Inc's market capitalization is USD 510.09M.

What does Neoleukin Therapeutics Inc do?

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome;